![](/img/cover-not-exists.png)
Should we accept a higher cost per health improvement for orphan drugs? A review and analysis of egalitarian arguments
Juth, Niklas, Henriksson, Martin, Gustavsson, Erik, Sandman, LarsJournal:
Bioethics
DOI:
10.1111/bioe.12786
Date:
July, 2020
File:
PDF, 422 KB
2020